866-997-4948(US-Canada Toll Free)

Opium (Opioid) Addiction - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Apr 2017

Category :

Diseases & Conditions

No. of Pages : 104 Pages

Opium (Opioid) Addiction - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Pipeline Review, H1 2017, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.

Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opium (Opioid) Addiction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 2, 4, 2, 13 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Opium (Opioid) Addiction - Overview 6
Opium (Opioid) Addiction - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Opium (Opioid) Addiction - Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Opium (Opioid) Addiction - Companies Involved in Therapeutics Development 23
Alkermes Plc 23
Aoxing Pharmaceutical Company Inc 23
Aquilus Pharmaceuticals Inc 24
BioCorRx Inc 24
BioDelivery Sciences International Inc 25
Camurus AB 25
Foresee Pharmaceuticals LLC 26
Heron Therapeutics Inc 26
Indivior Plc 27
INSYS Therapeutics Inc 28
Omeros Corp 29
Opiant Pharmaceuticals Inc 29
Orexigen Therapeutics Inc 30
Orexo AB 30
Pfizer Inc 31
Relmada Therapeutics Inc 31
Savant HWP Inc 32
Teva Pharmaceutical Industries Ltd 32
Titan Pharmaceuticals Inc 33
Zynerba Pharmaceuticals Inc 33
Opium (Opioid) Addiction - Drug Profiles 34
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 34
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 35
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 36
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 37
(buprenorphine hydrochloride + samidorphan l-malate) - Drug Profile 38
18-MC - Drug Profile 44
AQU-010 - Drug Profile 46
buprenorphine hydrochloride - Drug Profile 47
buprenorphine hydrochloride - Drug Profile 50
buprenorphine hydrochloride - Drug Profile 51
buprenorphine hydrochloride depot - Drug Profile 56
buprenorphine hydrochloride ER - Drug Profile 57
buprenorphine hydrochloride long acting - Drug Profile 59
buprenorphine hydrochloride SR - Drug Profile 60
cannabidiol - Drug Profile 63
cannabidiol - Drug Profile 64
Canquit-O - Drug Profile 67
FP-004 - Drug Profile 68
naltrexone hydrochloride - Drug Profile 69
naltrexone hydrochloride - Drug Profile 70
naltrexone hydrochloride SR - Drug Profile 71
OMS-405 - Drug Profile 73
OMS-527 - Drug Profile 75
OREX-1019 - Drug Profile 77
ORP-107 - Drug Profile 78
PF-4363467 - Drug Profile 79
PF-5006739 - Drug Profile 80
Small Molecule to Antagonize D3 Receptor for Opioid Addiction - Drug Profile 81
TEV-90109 - Drug Profile 82
Vaccine for Opioid Addiction - Drug Profile 83
Vaccine for Opium Addiction - Drug Profile 84
Opium (Opioid) Addiction - Dormant Projects 85
Opium (Opioid) Addiction - Discontinued Products 86
Opium (Opioid) Addiction - Product Development Milestones 87
Featured News & Press Releases 87
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 100
Disclaimer 101

List of Tables
Number of Products under Development for Opium (Opioid) Addiction, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Opium (Opioid) Addiction - Pipeline by Alkermes Plc, H1 2017
Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2017
Opium (Opioid) Addiction - Pipeline by Aquilus Pharmaceuticals Inc, H1 2017
Opium (Opioid) Addiction - Pipeline by BioCorRx Inc, H1 2017
Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International Inc, H1 2017
Opium (Opioid) Addiction - Pipeline by Camurus AB, H1 2017
Opium (Opioid) Addiction - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
Opium (Opioid) Addiction - Pipeline by Heron Therapeutics Inc, H1 2017
Opium (Opioid) Addiction - Pipeline by Indivior Plc, H1 2017
Opium (Opioid) Addiction - Pipeline by INSYS Therapeutics Inc, H1 2017
Opium (Opioid) Addiction - Pipeline by Omeros Corp, H1 2017
Opium (Opioid) Addiction - Pipeline by Opiant Pharmaceuticals Inc, H1 2017
Opium (Opioid) Addiction - Pipeline by Orexigen Therapeutics Inc, H1 2017
Opium (Opioid) Addiction - Pipeline by Orexo AB, H1 2017
Opium (Opioid) Addiction - Pipeline by Pfizer Inc, H1 2017
Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics Inc, H1 2017
Opium (Opioid) Addiction - Pipeline by Savant HWP Inc, H1 2017
Opium (Opioid) Addiction - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals Inc, H1 2017
Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017
Opium (Opioid) Addiction - Dormant Projects, H1 2017
Opium (Opioid) Addiction - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Opium (Opioid) Addiction, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *